Bicycle Therapeutics (BCYC) FCF Margin (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly FCF Margin came in at 7928.62% in Q2 2026, down 541889.0% YoY from N/an in Q2 2025, and down 5.54% on a QoQ basis from 7512.74% in Q1 2026.
Powered by 
Analysis
Bicycle Therapeutics (BCYC) FCF Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of FCF Margin data on file, last reported at 7928.62% in Q2 2026.
- Quarterly FCF Margin fell 541889.0% year-over-year to 7928.62% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 340.29% (up 75036.0% YoY) and the FY2025 annual result came in at 347.21%, up 12326.0% from the prior year.
- FCF Margin eased to 7928.62% in Q2 2026, from 7512.74% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 296.74% in Q2 2023 to a low of 7928.62% in Q2 2026.
- A 5-year average of 1438.41% and a median of 646.92% in 2025 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2025 — FCF Margin surged 89245 bps — and 2026, when it plunged 664099 bps.
- Tracing BCYC's FCF Margin over 5 years: stood at 378.06% in 2022, then slumped by 135 bps to 887.99% in 2023, then surged by 70 bps to 263.32% in 2024, then jumped by 84 bps to 41.54% in 2025, then sank by 18987 bps to 7928.62% in 2026.
- The last three FCF Margin figures came in at 7928.62% (Q2 2026), 7512.74% (Q1 2026), and 41.54% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Bicycle Therapeutics | 299.81 Mn | 299.81 Mn | - | -7,928.62% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,928.62% |
| Mar 31, 2026 | -7,512.74% |
| Dec 31, 2025 | -41.54% |
| Sep 30, 2025 | -612.30% |
| Jun 30, 2025 | -2,509.73% |
| Mar 31, 2025 | -871.75% |
| Dec 31, 2024 | -263.32% |
| Sep 30, 2024 | -1,504.75% |
| Jun 30, 2024 | -481.22% |
| Mar 31, 2024 | -362.93% |
| Dec 31, 2023 | -887.99% |
| Sep 30, 2023 | -28.53% |
| Jun 30, 2023 | 296.74% |
| Mar 31, 2023 | -990.81% |
| Dec 31, 2022 | -378.06% |
| Sep 30, 2022 | -291.28% |
| Jun 30, 2022 | -396.79% |
| Mar 31, 2022 | -807.15% |
| Dec 31, 2021 | -718.88% |
| Sep 30, 2021 | 497.32% |